Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-04-16

Clinical Trial Update: A Study of Guselkumab in Participants With Active Lupus Nephritis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating guselkumab for active lupus nephritis was terminated, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lupus Nephritis | Phase 2 | Status: TERMINATED | Results posted: 2024-04-16